Dialyzable low molecular weight antibody-augmenting factors (LMAAF) were found in the culture supernatant of human tonsillar lymphocytes which were not stimulated by antigen and/or mitogen
in vitro. Phagocyte-depleted nylon wool-adherent lymphocytes (M
-Ny
+ cells) were responsible for the release of the LMAAF. Marbrook's culture system was adopted to assay for the LMAAF. The M
-Ny
+ cells, which were cultured without antigen and/or without mitogen in the reservoir of Marbrook's diffusion culture vessel, released the LMAAF, which diffused across a dialysis membrane and significantly augmented the pokeweed mitogen (PWM)-induced plaque-forming cell (PFC) response of phagocyte-depleted lymphocytes (M
- cells) cultured in the inner vessel. Phagocyte-depleted nylon wool-passed lymphocytes (M
-Ny
- cells) cultured in the reservoir could not augment the PWM-induced PFC response of the M
- cells cultured in the inner vessel. The exuded fluid, which was the dialysate of the culture supernatant of the M
-Ny
+ cells ultrafiltrated with dialysis tubing, also enhanced the PFC response of M
- cells cultured in 24-well multi plates. The exuded fluid also augmented the total IgM and IgG production of human tonsillar and peripheral blood lymphocytes measured by enzyme-linked immunosorbent assay (ELISA) systems. Gel filtration chromatography on Sephadex G-25 Superfine column showed that the LMAAF activity was demonstrated in the fractions corresponding to a molecular weight (m.w.) of 362 to 1, 355 and a m.w. of 3, 560 to 5, 700, with a peak activity at about 4, 500 dalton. The LMAAF were inactivated by treatment with proteinase K, but not by trypsin, α-chymotrypsin, RNase, and DNase, and were stable when treated at 56C for 60min. The dialysates of culture supernatants from two out of seven Epstein-Barr virus (EBV)-transformed M
-Ny
+ cell lines showed LMAAF-like activity. These results indicate that phagocyte-depleted nylon wool-adherent lymphocytes, possibly B cells, release low molecular weight factors displaying augmenting activity for human antibody production
in vitro.
View full abstract